An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma

Claudette R Fraire1, Kavita Desai2,3, Indumathy Jagadeeswaran1

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.

Genes & Development
|April 16, 2025
PubMed

Insights

Mutations in microRNA processing genes DROSHA and DICER1 cause cancers resembling embryonic cells. Ablating these genes in mice led to pineal tumors, offering therapeutic targets by inhibiting proliferation drivers.

Area of Science:

  • Oncology
  • Developmental Biology
  • Molecular Biology

Background:

  • Mutations in microRNA processing genes DROSHA and DICER1 are implicated in cancers resembling embryonic progenitors.
  • MicroRNAs (miRNAs) are crucial regulators of gene expression, and their dysregulation can contribute to tumorigenesis.

Purpose of the Study:

  • To investigate the role of microRNA processing in tumorigenesis by studying the effects of DROSHA and DICER1 ablation in the developing pineal gland.
  • To emulate the pathogenesis of pineoblastoma, a brain tumor associated with undifferentiated pineal gland precursors.

Main Methods:

  • Ablation of Drosha or Dicer1 in the developing mouse pineal gland.
  • Analysis of miRNA expression, miRNA target gene derepression, and tumor characteristics.
  • Assessment of proliferation markers, pinealocyte maturation markers, and embryonic markers.

Main Results:

  • Mice with Drosha or Dicer1 loss developed pineal tumors with reduced microRNAs, including the let-7/miR-98-5p family.
  • These tumors exhibited derepression of miRNA target genes, upregulation of S-phase genes, and homeobox transcription factors, mimicking Rb1-loss tumors.
  • Inhibiting proliferation led to increased pinealocyte maturation markers but persistent elevation of some embryonic markers, such as the oncofetal transcription factor Plagl2.

Conclusions:

  • Tumors driven by the loss of microRNA processing exhibit distinct molecular features and can be therapeutically targeted.
  • Inhibiting downstream drivers of proliferation, like Plagl2 signaling, shows promise for treating these microRNA-deficient tumors.